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Human Papilloma Virus (HPV) is a major leading cause of Human Cancer. Through the HPV Prevention series we
would like to highlight the quality and the breadth of the research being carried out on the Control and
Prevention of HPV and HPV related disease. This series aims to bring together a diverse range of HPV related
specialties featuring research that has as ultimate goal insights into HPV related disease reduction. Articles within a
wide range of topics such as natural history studies, impact of screening interventions or impact of HPV vaccines
will be most welcome.Editorial
Human Papillomavirus (HPV) is responsible for over
five per cent of all cancers worldwide and of 15% of
cancer in women in developing countries [1]. HPV is
the necessary cause of cervical cancer [2], and is
thought to be the necessary cause for anal cancer [3].
Cervical cancer is the third most common cancer in
women worldwide with about 500,000 cases every year
and remains to be the second leading cause of cancer
death in women in less developed regions of the world
[4]. HPV is also partially related to the etiology of
vulva, vagina and penile cancers although these can-
cers are far less frequent, accounting for approximately
50,000 cases every year worldwide. Accumulated data
also suggest a potential implication of HPV in oropha-
ryngeal cancer among younger adults in wealthy popu-
lations [5]. Increasing trends in incidence are now
being seen for anal cancer [6] and for oropharyngeal
cancer [5] suggesting an increased background preva-
lence of oncogenic HPV types in affected populations.
HPV is also the cause of genital warts, a non-
malignant disease mainly related to HPV 6 and 11,
that frequently affect sexually active men and women.
Treatment of genital warts is tedious and not always
effective but a dramatic descent in incidence has been
shown in HPV vaccinated population [7].
Research on HPV and cancer has drawn a scenario in
which a major reduction of HPV related disease is fea-
sible through population based prevention strategies.Correspondence: s.sanjose@iconcologia.net
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reproduction in any medium, provided the orThese include routine HPV vaccination of pre-adolescent
and young women, improvement of cervical cancer
screening strategies through HPV based technologies,
adaptation of preventive strategies using cost-benefit
models and inclusion in the health priority lists the wide
range of HPV related disease [8].
While our knowledge on the natural history and pre-
vention mechanisms of cervical cancer has increased
enormously during the last 30 years, there remain major
unanswered issues [9]. A wide range of topics have been
proposed and many of them will certainly be a priority
for this HPV Prevention series. A question such as what
is the role of micro RNA in HPV pathogenesis, why is
the HPV 16 the most successful mucosotropic HPV type
or how can advocacy deal with anti-vaccine activism are
all relevant queries that can have a space in this collec-
tion if structured into research projects. It is clear that
we need to open the focus of our research from cervical
cancer to a much wider scope of HPV related diseases.
Finally, ancillary research (i.e. management or associa-
tions with other STIs or educational approach to pre-
adolescent health) can also be of interest in this series if
linked to HPV related disease.
HPV related disease is not an entity that navigates on
its own. It represents a complex mixture of genetics,
micro-environment, behaviour and social influences.
With the HPV Prevention series we hope to wider our
minds, to increase our capacity for action and ultimately,
to increase the health of our population.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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